Skip to content
Home/Companies/Biotech/Carisma Therapeutics

Carisma Therapeutics

Biotech·United States·Exited 2023·Held 5yr
Entry
2018
Hold
5yr
Exit
2023

Who owns Carisma Therapeutics?

Carisma Therapeutics was owned by Wellington Partners through Wellington Partners Life Sciences (1998 vintage) from 2018 to 2023, exited via IPO.

Hand-verified · updated 2026-08-10

Wellington Partners
Investor
Wellington Partners
Wellington Partners Life Sciences · 1998 · VC

Key facts

HQUnited States
SectorBiotech
StatusAcquired
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2023

More from Wellington Partners Life Sciences

Other portfolio companies in the same fund.

Beren Therapeutics
Active
BiotechUnited States· 2026
Nuclidium
Active
BiotechSwitzerland· 2026
CorFlow Therapeutics
CorFlow Therapeutics
Active
MedTechSwitzerland· 2024
SciRhom
Active
BiotechGermany· 2024
Nyra Health
Active
HealthTechAustria· 2023
Seamless Therapeutics
Seamless Therapeutics
Active
BiotechGermany· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Carisma Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Carisma Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue